Genotype-guided diagnosis in familial hypercholesterolemia: Population burden and cascade screening

Current Opinion in Lipidology

Volumn 28, Issue 2, 2017, Pages 136-143

  Hopkins, Paul N ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

APOB; autosomal dominant hypercholesterolemia; coronary artery disease; familial hypercholesterolemia; genetic testing; LDLR; PCSK9; prevalence; screening

Indexed keywords

CORONARY ARTERY DISEASE; DEATH; EARLY DIAGNOSIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC SCREENING; GENOTYPE; HUMAN; PEDIGREE; POPULATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; COMPLICATION; GENETICS; MASS SCREENING; MUTATION; PROCEDURES;

EARLY DIAGNOSIS; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; MUTATION; PREVALENCE;

EID: 85007473595     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000388     Document Type: Review

References (38)

1. Wintjens R, Bozon D, Belabbas K, et al. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France. J Lipid Res 2016; 57:482-491.
2. Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ Cardiovasc Genet 2015; 8:823-831.
3. Fouchier SW, Dallinga-Thie GM, Meijers JC, et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res 2014; 115:552-555.
4. Khoury MJ, Evans JP. A public health perspective on a national precision medicine cohort: balancing long-Term knowledge generation with early health benefit. JAMA 2015; 313:2117-2118.
5. Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015; 518:102-106.
6. Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016; 67:2578-2589.
7. Nordestgaard BG, Chapman MJ, Humphries SE, et al., European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478a-3490a.
8. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36:560-565.
9. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016; 37:1384-1394.
10. Watts GF, Shaw JE, Pang J, et al. Prevalence and treatment of familial hypercholesterolaemia in Australian communities. Int J Cardiol 2015; 185:69-71.
11. Shi Z, Yuan B, Zhao D, et al. Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a community population. Int J Cardiol 2014; 174:834-836.
12. Wald DS, Bestwick JP, Morris JK, et al. Child-parent familial hypercholesterolemia screening in primary care. N Engl J Med 2016; 375:1628-1637.
13. de Ferranti SD, Rodday AM, Mendelson MM, et al. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation 2016; 133:1067-1072.
14. Miller PE, Martin SS, Toth PP, et al. Screening and advanced lipid phenotyping in familial hypercholesterolemia: The very large database of lipids study-17 (VLDL-17). J Clin Lipidol 2015; 9:676-683.
15. Safarova MS, Liu H, Kullo IJ. Rapid identification of familial hypercholesterolemia from electronic health records: The SEARCH study. J Clin Lipidol 2016; 10:1230-1239.
16. Knickelbine T, Lui M, Garberich R, et al. Familial hypercholesterolemia in a large ambulatory population: Statin use, optimal treatment, and identification for advanced medical therapies. J Clin Lipidol 2016; 10:1182-1187.
17. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37:2999-3058.
18. Piepoli MF, Hoes AW, Agewall S, et al., Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37:2315-2381.
19. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative
20. Williams RR, Schumacher MC, Barlow GK, et al. Documented need for more effective diagnosis and treatment of familial hypercholesterolemia according to data from 502 heterozygotes in Utah. Am J Cardiol 1993; 72:18D-24D.
21. Morris JK, Wald DS, Wald NJ. The evaluation of cascade testing for familial hypercholesterolemia. Am J Med Genet A 2012; 158A:78-84.
22. Klancar G, Groselj U, Kovac J, et al. Universal screening for familial hypercholesterolemia in children. J Am Coll Cardiol 2015; 66:1250-1257.
23. Norsworthy PJ, Vandrovcova J, Thomas ER, et al. Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: A population-based study. BMC Med Genet 2014; 15:70.
24. Wang J, Dron JS, Ban MR, et al. Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically. Arterioscler Thromb Vasc Biol 2016; 36:2439-2445.
25. Hegele RA, Ban MR, Cao H, et al. Targeted next-generation sequencing in monogenic dyslipidemias. Curr Opin Lipidol 2015; 26:103-113.
26. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. Lancet 2013; 381:1293-1301.
27. Fouchier SW, Hutten BA, Defesche JC. Current novel-gene-finding strategy for autosomal-dominant hypercholesterolaemia needs refinement. J Med Genet 2015; 52:80-84.
28. Besseling J, Reitsma JB, Gaudet D, et al. Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia. Eur Heart J 2016. (in press).
29. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72:171-176.
30. Day INM, Hopkins PN. Clinical criteria for the diagnosis of FH. Familial Hypercholesterolemia. Report of a WHO Consultation. Paris: World Health Organization; 1997.
31. Starr B, Hadfield SG, Hutten BA, et al. Development of sensitive and specific age-And gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008; 46:791-803.
32. Kusters DM, Huijgen R, Defesche JC, et al. Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the lowdensity lipoprotein receptor and apolipoprotein B genes. Neth Heart J 2011; 19:175-182.
33. Hopkins PN. Familial hypercholesterolemia. Curr Treat Options Cardiovasc Med 2002; 4:121-128.
34. Koopal C, Visseren FL, Marais AD, et al. Tendon xanthomas: not always familial hypercholesterolemia. J Clin Lipidol 2016; 10:1262-1265.
35. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49:476-488.
36. Hopkins PN. Encouraging appropriate treatment for familial hypercholesterolemia. Clin Lipidol 2010; 5:339-354.
37. Jensen HK, Jensen LG, Hansen PS, et al. A G-1-To-A acceptor splice site LDLR mutant allele leads to reduced relative transcript levels in patients with heterozygous familial hypercholesterolemia. Clin Genet 1996; 49:175-179.
38. Laufs U, Parhofer KG. Simplified algorithm to facilitate communication of familial hypercholesterolaemia. Eur Heart J 2015; 36:3004-3006.